OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.
about
Oncolytic viruses as therapeutic cancer vaccinesImmune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsCancer immunotherapy: the beginning of the end of cancer?Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeOncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic ApplicationsProgresses towards safe and efficient gene therapy vectorsVaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.Therapeutic cancer vaccines: past, present, and futureCancer vaccinesOncolytic viruses as anticancer vaccinesOvercoming tumor immune evasion with an unique arbovirusOncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory moleculesOncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.Systemic CD8+ T cell-mediated tumoricidal effects by intratumoral treatment of oncolytic herpes simplex virus with the agonistic monoclonal antibody for murine glucocorticoid-induced tumor necrosis factor receptor.Melanoma vaccines: mixed past, promising future.Current treatment of locoregional recurrence of melanoma.Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancerGene therapy: implications for craniofacial regeneration.Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasEffect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.Oncolytic viruses in the treatment of bladder cancerIpilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Life after death: targeting high mobility group box 1 in emergent cancer therapies.Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.First oncolytic virus approved for melanoma immunotherapy.The Impact of Macrophage- and Microglia-Secreted TNFα on Oncolytic HSV-1 Therapy in the Glioblastoma Tumor MicroenvironmentCancer vaccines: Looking to the future.Oncolytic herpes viruses, chemotherapeutics, and other cancer drugsImmunotherapy in the management of melanoma: current status.Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapyEmerging cancer vaccines: the promise of genetic vectors.Cytokines in cancer immunotherapy.Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.
P2860
Q21245758-7190C871-ED27-431B-8C8B-F69298230E55Q24596171-0AD0CBFB-934F-4308-98D4-F70E58DD9ED1Q24617027-0B202C49-52BE-44C7-BDE9-F19BA61989CFQ26752277-682D0509-32D8-490C-9C91-E3B501CBC4ECQ26769977-9D98BC2E-D331-4A21-85AE-D19A7C1628AFQ26776553-7B655082-A2B9-4D22-9973-B8927DF3F14CQ26781432-1E068059-1D06-4318-B8A1-5BAF66DD0574Q26796314-39C2D911-1FE4-4ABC-B954-1EB6A4F4491EQ26863283-34E9AAF2-059A-4B6C-AE22-3C4EE6654F40Q27024438-95A77FDF-B46A-45FF-BAE8-50530A788581Q27025600-DFFC3254-642A-4FC6-860E-9574BD5E748CQ28081774-BE46BB9C-8597-4229-AB50-EED23619C37BQ33579883-907B3D48-B1F5-4C55-951B-BEFA68EF43AAQ33637231-D4B390CD-B42D-4FFA-88A8-FEF916CAE450Q33899522-2D3E1DB5-DD81-4D6C-93AF-CB76CD19613CQ34020594-68A6A654-BF6B-463F-9224-CF84F159717DQ34235476-37D36CB9-07B3-430A-A6BB-A1FF219B94E9Q34888462-48F2AEB4-DEF8-4C1D-B3C5-76AC9A85901BQ35596563-F234ED68-FE10-486A-8656-E9746773DEE8Q35739482-410E96B8-0A0F-4E4E-9947-84DB769C9259Q35764559-7588F3F5-F70C-4437-93CF-AAC16218F0E1Q35845352-F1F13B6B-26FF-4CCF-ABC9-320E9FC182C2Q35867997-77CCBC46-F24F-44B2-9FB2-503B52B68B82Q36014043-78E79467-71EA-4BEB-82BE-C5B3E5D20AEFQ36147934-8DB8E584-1DA2-4EBD-B685-6822478203DAQ36292634-8A55F92E-73F9-4364-85B1-1A28C50E2028Q36298608-D0BA57B2-EEAC-4B8C-A1DC-3AEA047057ECQ36562901-2B8A210A-67DA-4891-BCF3-E16CD05EE4ADQ36597119-9462D144-FF17-46B3-9EB9-723801D1FF86Q36597333-C27AAEFC-C7AD-4C4B-9DAC-0BBDE4C4BFD5Q36658280-175DBEAD-6C09-4178-8783-C1F3339E7519Q36866158-22B893E3-ED7C-43F3-82B4-BA4332076668Q37031896-38DCF719-66AF-459B-8531-2A6732535BE6Q37054958-BB4FC42E-129A-4AF9-AF5A-2E38985F1C12Q37069810-E4FDF336-837D-4F4C-8856-2DB4084C2F8FQ37104963-14C2F1BC-C9EA-4C30-850A-1AF6A4AED24BQ37137464-47AB9527-8E08-4B20-8E86-742FC2121BB7Q37148152-CB0A5FCA-0B83-40E0-B30B-7D4CEC3D0E47Q37317439-B2743F69-0F0A-4AD4-9A15-20909C2076A8Q37459624-AD1CBCD1-2168-4FE1-B6CE-E2D1D42259D3
P2860
OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
OPTIM trial: a Phase III trial ...... able stage III or IV melanoma.
@en
OPTIM trial: a Phase III trial ...... able stage III or IV melanoma.
@nl
type
label
OPTIM trial: a Phase III trial ...... able stage III or IV melanoma.
@en
OPTIM trial: a Phase III trial ...... able stage III or IV melanoma.
@nl
prefLabel
OPTIM trial: a Phase III trial ...... able stage III or IV melanoma.
@en
OPTIM trial: a Phase III trial ...... able stage III or IV melanoma.
@nl
P2860
P356
P1433
P1476
OPTIM trial: a Phase III trial ...... able stage III or IV melanoma.
@en
P2093
Howard L Kaufman
Steven D Bines
P2860
P304
P356
10.2217/FON.10.66
P407
P577
2010-06-01T00:00:00Z